We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oncology Drug Reference Sheet: Nivolumab and Relatlimab-Rmbw.
- Authors
Weimer, Jaime
- Abstract
The article profiles the fixed-dose combination therapy nivolumab and relatlimab-rmbw for the treatment of unresectable or metastatic melanoma in 2022. Topics discussed include the combination therapy's category/class, mechanism of action, indication, dosing, administration, and adverse reactions. Also noted are its considerations for nursing, patient education, and safe handling.
- Subjects
THERAPEUTIC use of antineoplastic agents; DRUG approval; IMMUNE checkpoint inhibitors; MELANOMA; METASTASIS; UNITED States. Food &; Drug Administration; NIVOLUMAB; PHARMACY information services; PATIENT education; IMMUNOTHERAPY; PATIENT safety; PHARMACODYNAMICS
- Publication
ONS Voice, 2022, Vol 37, Issue 8, p27
- ISSN
2475-6938
- Publication type
Article